The Passage Study

Currently Recruiting

23 Mar 2026

Up to $8,450

Melbourne, Australia

This clinical trial is sponsored by a pharmaceutical company. It is investigating a potential drug (the study drug) for inflammatory and fibrotic conditions. These include long-term digestive diseases such as ulcerative colitis and Crohn’s disease, where ongoing inflammation and scarring can damage the intestines. Some current treatments may not work for everyone and can cause significant side effects. This trial is designed to assess the safety and potential benefits of an investigational study drug that may offer an additional option for people who do not respond well to existing therapies.

Apply now Speak with us

Join our clinical trial

This is not a first-in-human (FIH) study, meaning it is not the first time the potential treatment is being tested in people. The study has been carefully designed with strict safety protocols and has been approved by an independent ethics committee.

Before joining, you’ll receive detailed information about the study, meet with a doctor, and have the chance to ask any questions.

Nucleus Network - Image

What to expect

  • Participation in a monitored clinical environment
  • Study visits scheduled
  • Support from a professional medical team
  • Reimbursement for your time and commitment

Trial details

Study duration

6 nights stay, 6 follow-up visits.

Study medication

Administered via subcutaneous injection

Additional Eligibility

  • Weight above 50-100kg
  • Non-smokers or smoking no more than 5 cigarettes per week

Are you a match?

Age

18 - 55 years old

Remuneration

Up to $8,450 *with screening reimbursement. Please see T&Cs.

Gender

Male or Female

BMI

BMI 18 - 32 kg/m2

Commitment

6 nights, 6 clinic visits

Medical condition

Not taking any medications

Register Your Interest for The Passage Study

Thank you for your interest in participating in a clinical trial. This study is evaluating an investigational drug that may help address conditions involving inflammation and tissue scarring.

 The study is scheduled for March 2026, and you’ll need to be available during that time.

This form takes 2–3 minutes to complete, and your information will remain confidential, used only to assess your eligibility for current or future research studies.
Step 1 of 3
Contact Information




The phone number you have entered does not appear to be a valid active Australian phone number. Please check your details and enter a valid Australian phone number starting with +61

Nucleus Network does not currently conduct clinical trials in your state. If you would like to receive study information should this situation change, please complete and submit this form.
Personal Information

This includes registering your interest with the Centre for Clinical Studies, Q-Pharm or Nucleus Network

Please call us on 1300 590 848 or schedule a call.


What is your date of birth?
Day Month Year

You need to be at least 18 years old to participate in clinical trials.


cm

kg





















Step 2 of 3
Medical History

We define an allergy as severe if symptoms include mouth/throat/face swelling, shortness of breath or a whole-body rash, or if it required hospitalisation

We regularly have studies that allow participants who are (social) smokers.

We regularly have studies that allow for/require participants with asthma.



We regularly have studies that allow for/require participants with medical conditions.

Medications & Contraception Requirements

We regularly have studies that allow participants with depression that is well-managed on a stable dose of medication.

If the only prescription medication you currently use is hormonal contraception and/or Ventolin, please select No above. We regularly have studies that allow for participants who take a stable dose of prescription medication.


  • Abstinence from sex with anyone of the opposite sex for at least 2 months
  • Using a condom + your female sexual partner(s) using a separate form of birth control
  • You or your sexual partner(s) had a vasectomy/hysterectomy
  • Your sexual partner(s) are post-menopausal


Only you taking birth control or your partner(s) using a condom is not an acceptable option, but using both together is. The morning after pill is not an acceptable form of birth control.

  • Abstinence, by choice, from sex with anyone of the opposite sex for the last 2 months + remaining abstinent for at least 2 months after study participation
  • You using birth control + your male sexual partner(s) using a condom
  • You or your sexual partner(s) had a hysterectomy/vasectomy
  • You are post-menopausal



Step 3 of 3
Referral Information



Consent to Information Use and Future Contact